| Janis Coachman, LPN | |
|
1 Va Ctr, Augusta, ME 04330-6719 | |
| (207) 402-5321 | |
| Not Available |
| Full Name | Janis Coachman |
|---|---|
| Gender | Female |
| Speciality | Licensed Practical Nurse |
| Location | 1 Va Ctr, Augusta, Maine |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1306232681 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 164W00000X | Licensed Practical Nurse | LPN13286 (Maine) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Janis Coachman, LPN Po Box 1564, Auburn, ME 04211-1564 Ph: (207) 402-5321 | Janis Coachman, LPN 1 Va Ctr, Augusta, ME 04330-6719 Ph: (207) 402-5321 |
News Archive
Elan Corporation, plc today announced that findings from a Phase II study which suggested bapineuzumab reduced amyloid-beta deposits in the brains of Alzheimer's disease patients as measured using a neuroimaging technique known as [11C]PiB PET, were published in the February 28, 2010 online edition of Lancet Neurology. Bapineuzumab is a compound under development by Pfizer and Janssen Alzheimer Immunotherapy, a Johnson & Johnson subsidiary in which Elan holds a minority equity interest.
Four University of California, San Diego School of Medicine researchers have been selected to receive the newly established National Cancer Institute (NCI) Outstanding Investigator Award. The multi-million dollar awards fund new projects that have an unusual potential in cancer research over seven years.
ImmunoGen, Inc., a biotechnology company that develops targeted antibody-based anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced positive clinical data with the Company's IMGN901 (lorvotuzumab mertansine) product candidate as featured in an oral presentation at the ASCO 2011 Annual Meeting in Chicago.
Oasmia Pharmaceutical AB, developer of a new generation of drugs within human and veterinary oncology, announced today the topline findings from a head-to-head comparison study of its lead human cancer product candidate Paclical and Celgene's Abraxane, which show similar pharmacokinetic (PK) profiles of the two products. The study was conducted in women with metastatic breast cancer.
CVS Caremark today announced results of a survey of the company's specialty pharmacy patients that provides insights into their views on medication adherence and their perceptions about the role of their specialty pharmacy. The survey results show nearly 70 percent of respondents believe their specialty pharmacy team played an important role in encouraging them to take their specialty medications as prescribed.
› Verified 9 days ago
Laurie Ducat, Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 151 Capitol St Ste 4, Augusta, ME 04330 Phone: 207-512-8549 | |
Lisaann Dresser, Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 151 Capitol St Ste 4, Augusta, ME 04330 Phone: 207-512-8549 | |
Christine Greenwood, Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 151 Capitol St Ste 4, Augusta, ME 04330 Phone: 207-512-8549 | |
Jenica Kirkbride, Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 151 Capitol St Ste 4, Augusta, ME 04330 Phone: 207-512-8552 | |
James Elmore, Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 151 Capitol St Ste 4, Augusta, ME 04330 Phone: 207-512-8549 | |
Jessica Brown, Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 151 Capitol St Ste 4, Augusta, ME 04330 Phone: 207-512-8549 |